BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 13, 2012
 |  BioCentury  |  Emerging Company Profile

Abide: Selecting serine hydrolases

Abide expanding serine hydrolases as targets, starting in neuropathic pain

Abide Therapeutics Inc. is developing an approach to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. Most of the new targets will require significant preclinical characterization and validation, which Abide plans to do with partners.

Serine hydrolases cleave bonds in proteins, peptides and small molecules to regulate processes from blood clotting to nervous system signaling. There are approved small molecule inhibitors targeting six human serine hydrolases, including acetylcholinesterase (AChE) and dipeptidyl peptidase-4 (DPP-4). Marketed beta lactam antibiotics and HCV NS3/4A protease inhibitors also target serine hydrolases.

Abide believes the therapeutic potential of the remaining 250 or so human serine hydrolases and the large number of viral and bacterial enzymes has not been sufficiently explored because of difficulty in finding selective compounds.

According to President and CEO Alan Ezekowitz, companies have brought compounds they thought were highly selective for a single serine hydrolase into the clinic only to find they were not. He noted early DPP-4 inhibitors failed...

Read the full 834 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >